AusCann Group Holdings Ltd (ASX: AC8) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Auscann Group Holdings Ltd Chart and Price Data
Fundamentals Data provided by Morningstar.
Data provided by Morningstar.
Market Cap
$36.57 million
P/E Ratio
N/A
Dividend Yield
N/A
Shares Outstanding
440.55 million
Earnings per share
-0.030
Dividend per share
N/A
Year To Date Return
-57.44%
Earnings Yield
N/A
Franking
N/A
Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
AusCann Group Holdings Ltd (ASX: AC8)
Latest News
Cannabis Shares
Blazing it? How the top ASX cannabis shares performed in FY21
Cannabis Shares
CBD to be sold in pharmacies, ASX cannabis shares react
Share Market News
Why the AusCann (ASX:AC8) share price jumped 14% higher today
Best Shares
5 top ASX cannabis shares in 2020
Share Gainers
ASX pot stocks have been skyrocketing in December
Share Market News
Elixinol (ASX:EXL) share price tumbles on capital raising update
Share Market News
ASX stock of the day: CannPal Animal Therapeutics (ASX:CP1) shares shoot 25%
Share Market News
Look out for the Auscann (ASX:AC8) and Cannpal (ASX:CP1) share prices post trading halt
AC8 ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
| Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
|---|---|---|---|---|---|
| YesNo |
About AusCann Group Holdings Ltd
Auscann Group Holdings Ltd (ASX: AC8) is a pharmaceutical company based in Western Australia. Its focus is on developing, producing and distributing a range of cannabinoid treatments for use in Australia and internationally.
According to Auscann, the company’s products are the result of a stringent development program that aims to produce stable and effective cannabinoid-based medicines. Auscann also seeks to generate clinical evidence supporting the efficacy of its products to support further market penetration.
Whilst working directly with patients, Auscann’s primary focus is on providing healthcare professionals with optimal treatment solutions to help them better care for their patients. The company also provides healthcare professionals with the tools to personalise and adjust dosage and treatment programs for each individual.
AusCann was readmitted to the ASX in early 2017 after it was acquired by the already listed company TW Holdings Limited. In the months following, the Auscann share price surged by nearly 200%. Within 12 months, the Auscann share price had gone on to deliver growth of nearly 500% over its ASX readmittance value. Since then however, the Auscann share price has trended lower and has not traded over $1 since late 2018.
AC8 Share Price History Data provided by Morningstar.
| Date | Close | Change | % Change | Volume | Open | High | Low |
|---|---|---|---|---|---|---|---|
| 03 Dec 2021 | $0.08 | $0.00 | 0.00% | 331,773 | $0.08 | $0.09 | $0.08 |
| 02 Dec 2021 | $0.09 | $0.00 | 0.00% | 225,858 | $0.08 | $0.09 | $0.08 |
| 01 Dec 2021 | $0.08 | $0.00 | 0.00% | 315,818 | $0.08 | $0.08 | $0.08 |
| 30 Nov 2021 | $0.08 | $0.00 | 0.00% | 223,586 | $0.09 | $0.09 | $0.08 |
| 29 Nov 2021 | $0.08 | $0.00 | 0.00% | 899,286 | $0.09 | $0.09 | $0.08 |
| 26 Nov 2021 | $0.09 | $0.00 | 0.00% | 275,116 | $0.09 | $0.09 | $0.09 |
| 25 Nov 2021 | $0.09 | $0.00 | 0.00% | 1,002,413 | $0.09 | $0.09 | $0.09 |
| 24 Nov 2021 | $0.09 | $0.00 | 0.00% | 1,590,493 | $0.09 | $0.09 | $0.09 |
| 23 Nov 2021 | $0.09 | $-0.01 | -10.20% | 1,357,468 | $0.10 | $0.10 | $0.09 |
| 22 Nov 2021 | $0.10 | $-0.01 | -9.52% | 191,058 | $0.10 | $0.10 | $0.10 |
| 19 Nov 2021 | $0.11 | $0.01 | 10.10% | 210,651 | $0.10 | $0.11 | $0.10 |
| 18 Nov 2021 | $0.10 | $0.00 | 0.00% | 605,330 | $0.10 | $0.11 | $0.10 |
| 17 Nov 2021 | $0.10 | $0.00 | 0.00% | 203,728 | $0.11 | $0.11 | $0.10 |
| 16 Nov 2021 | $0.11 | $0.00 | 0.00% | 805,853 | $0.11 | $0.11 | $0.11 |
| 15 Nov 2021 | $0.11 | $0.00 | 0.00% | 523,590 | $0.11 | $0.11 | $0.11 |
| 12 Nov 2021 | $0.10 | $0.01 | 10.53% | 485,932 | $0.10 | $0.11 | $0.10 |
| 11 Nov 2021 | $0.10 | $0.00 | 0.00% | 191,031 | $0.10 | $0.10 | $0.10 |
| 10 Nov 2021 | $0.10 | $0.00 | 0.00% | 891,770 | $0.10 | $0.10 | $0.10 |
| 09 Nov 2021 | $0.10 | $0.00 | 0.00% | 979,167 | $0.10 | $0.11 | $0.10 |
| 08 Nov 2021 | $0.10 | $0.00 | 0.00% | 169,952 | $0.10 | $0.10 | $0.10 |
| 05 Nov 2021 | $0.10 | $0.00 | 0.00% | 126,835 | $0.10 | $0.10 | $0.10 |
Director Transactions Data provided by Morningstar.
| Date | Director | Type | Amount | Value | Notes |
|---|---|---|---|---|---|
| 04 Nov 2021 | Krista Bates | Transfer | 427 | $44,000 |
Off-market transfer.
|
| 04 Nov 2021 | Krista Bates | Transfer | 427 | $44,000 |
Off-market transfer.
|
| 14 May 2021 | Geoff Starr | Buy | 100 | $11,500 |
On-market trade.
|
| 15 Apr 2021 | Robert (Max) Johnston | Buy | 110 | $15,400 |
On-market trade.
|
| 18 Mar 2021 | Krista Bates | Buy | 292 | $42,412 |
As advised by the company. Shares acquired under the Scheme of
Arrangement with CannPal Animal Therapeutics Ltd. |
| 18 Mar 2021 | Christopher (Chris) Mews | Buy | 279 | $40,554 |
As advised by the company. Shares acquired under the Scheme of
Arrangement with CannPal Animal Therapeutics Ltd (ASX:CP1) under which CP1 shareholders received 1.3 new AC8 shares for every 1 CP1 share held at the record date. |
| 18 Mar 2021 | Robert (Max) Johnston | Buy | 390 | $56,550 |
As advised by the company. Shares acquired under the Scheme of
Arrangement with CannPal Animal Therapeutics Ltd. |
Directors & Management Data provided by Morningstar.
| Name | Title | Start Date | Profile |
|---|---|---|---|
| Ms Krista Bates | Non-Executive DirectorInterim Chairperson | Dec 2019 |
Ms Bates has 21 years of expertise in the legal market. She was a Partner at leading Western Australian law firm Lavan specialising in Corporate law and was
Head of Mining & Resources and the Medical Cannabis Group. |
| Mr Geoff Starr | Non-Executive Director | Apr 2021 |
MR Starr brings over 35 years of executive experience to the company, 15 years of which was at Managing Director or CEO level, gained all around the world, but
especially in Asia, Europe and Australia/New Zealand. |
| Mr Robert Clifford | Non-Executive Director | Apr 2021 |
Mr Clifford has more than 25 years of experience in Food and beverage industry. Mr Clifford has held various executive management positions in Perth, Canberra and Macau.
|
| Dr Kathryn (Kate) Claire Adams | Non-Executive Director | Apr 2021 |
Dr Adams is an entrepreneur and Veterinarian. Dr Adams has held senior
leadership roles for the Federal Attorney-General's Portfolio including as an Analyst, Principal Adviser and Chief of Staff for a number of Royal Commissions. |
| Mr Christopher (Chris) Lee Mews | Non-Executive Director | Dec 2019 |
Mr Mews is an experienced non-executive director with over 20 years in the financial services sector, having held senior positions in finance, corporate secretarial and compliance in listed and unlisted companies.
|
| Mr Layton Patrick Mills | Chief Executive Officer | Mar 2021 |
-
|
| Ms Susan Patricia Park | Company Secretary | Oct 2016 |
-
|
| Mr Quentin Heath Megson | Chief Financial OfficerJoint Company Secretary | Feb 2019 |
-
|
| Layton Patrick Mills | Chief Executive Officer |
-
|
|
| Quentin Heath Megson | Chief Financial OfficerJoint Company Secretary |
-
|
|
| Susan Patricia Park | Company Secretary |
-
|
Top Shareholders Data provided by Morningstar.
| Name | Shares | Capital |
|---|---|---|
| The Trust Company (Australia) Limited (MOF A/C) | 56,379,750 | 12.80% |
| Citicorp Nominees Pty Limited | 12,263,518 | 2.78% |
| Mr Layton Patrick Mills (DJs Family A/C) | 11,387,582 | 2.58% |
| Ms Tania Maree Vidovic (Star V Family A/C) | 7,400,874 | 1.68% |
| Merrill Lynch (Australia) Nominees Pty Limited | 5,754,883 | 1.31% |
| Mr George Chien Hsun Lu & Mrs Jenny Chin Pao Lu | 4,958,999 | 1.13% |
| Pepaanne Pty Ltd (The Chapman Family A/C) | 4,600,000 | 1.04% |
| Mr Warren Sidney Langman | 4,235,928 | 0.96% |
| HSBC Custody Nominees (Australia) Limited | 3,340,101 | 0.76% |
| Bnp Paribas Nominees Pty Ltd (Ib Au Noms Retailclient Drp) | 2,813,910 | 0.64% |
| Bnp Paribas Nominees Pty Ltd Acf Clearstream | 2,639,184 | 0.60% |
| Ajava Holdings Pty Ltd | 2,600,000 | 0.59% |
| Miss Xiaodan Fu | 2,577,402 | 0.59% |
| Mr George Chien-Hsun Lu | 2,569,999 | 0.58% |
| Bnp Paribas Noms Pty Ltd (DRP) | 2,563,129 | 0.58% |
| Marcus Kelly Property Developments Pty Ltd | 2,500,000 | 0.57% |
| Wil & Jack Pty Ltd (Wil & Jack Family A/C) | 2,348,106 | 0.53% |
| Lus International Limited | 2,339,999 | 0.53% |
| Mr John Andrew Rodgers (John Rodgers Family A/C) | 2,316,372 | 0.53% |
| Ms Kate Eloise Toft (Johnstone Family A/C) | 2,237,521 | 0.51% |